Palatin is currently conducting a Phase 2 clinical trial with the MC4R agonist bremelanotide in combination with tirzepatide, a GLP-1/GIP. Enrollment is complete, and topline results are expected ...

Technologies announced that preclinical data from the Company’s melanocortin 4 receptor, or MC4R, selective PL7737 obesity ...

Palatin (PTN) Technologies announced that preclinical data from the Company’s melanocortin 4 receptor, or MC4R, selective PL7737 obesity program will be highlighted in a poster presentation at ...

Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual ...

A copy of the poster can be found on Palatin's website ... patients with the MC4R agonist bremelanotide in combination with tirzepatide with results expected in 1Q 2025. About the Peptide ...

Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024 Top ...

Palatin is currently conducting a Phase 2 clinical trial with the MC4R agonist bremelanotide in combination with tirzepatide, a GLP-1/GIP. Enrollment is complete, and topline results are expected in ...

A copy of the poster can be found on Palatin’s website ... 2 clinical trial in obese patients with the MC4R agonist bremelanotide in combination with tirzepatide with results expected in 1Q 2025.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.